5AM Ventures

Total investments

191

Average round size

39M

Portfolio companies

92

Rounds per year

8.68

Lead investments

40

Follow on index

0.51

Exits

40

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

5AM Ventures appeared to be the VC, which was created in 2002. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Menlo Park.

The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Ikaria, Relypsa We can highlight the next thriving fund investment areas, such as Life Science, Therapeutics.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the 5AM Ventures, startups are often financed by Clarus Ventures, ARCH Venture Partners, Sprout Group. The meaningful sponsors for the fund in investment in the same round are Roche Venture Fund, Frazier Healthcare Partners, Clarus Ventures. In the next rounds fund is usually obtained by ARCH Venture Partners, Roche Venture Fund, Aravis Ventures.

The current fund was established by Andrew Schwab, John Diekman. Besides them, we counted 8 critical employees of this fund in our database.

The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 12 percentage points more often commits exit comparing to other companies. When the investment is from 5AM Ventures the average startup value is 10-50 millions dollars. Opposing the other organizations, this 5AM Ventures works on 8 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2018. The fund is constantly included in 7-12 deals per year.

Show more

Investments analytics

Analytics

Total investments
191
Lead investments
40
Exits
40
Rounds per year
8.68
Follow on index
0.51
Investments by industry
  • Biotechnology (171)
  • Health Care (104)
  • Therapeutics (86)
  • Pharmaceutical (48)
  • Medical (43)
  • Show 32 more
Investments by region
  • United States (174)
  • Switzerland (7)
  • United Kingdom (3)
  • Sweden (2)
  • Singapore (1)
  • Show 1 more
Peak activity year
2018
Number of Unicorns
5
Number of Decacorns
5
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
118M
Group Appearance index
0.95
Avg. company exit year
6
Avg. multiplicator
2.69
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Karius 02 May 2024 Biotechnology, Information Technology, Genetics, Life Science Late Stage Venture 100M United States, California, Redwood City
Nido Biosciences 08 Sep 2020 Biotechnology, Health Care, Personal Health Early Stage Venture 18M United States, Massachusetts, Boston

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.